Optinose reports preliminary fourth quarter 2024 XHANCE revenue of $22.4 million, indicating sustained prescription growth. Full results expected in March.
Quiver AI Summary
Optinose, a pharmaceutical company specializing in treatments for ear, nose, and throat (ENT) and allergy issues, reported preliminary unaudited net product revenue of $22.4 million for XHANCE (fluticasone propionate) for the fourth quarter ended December 31, 2024. This figure aligns with the company’s earlier guidance and reflects approximately 20% growth in prescriptions from the previous quarter. CEO Ramy Mahmoud highlighted the company’s focus on commercial execution and revenue growth as it looks forward to more detailed financial results and corporate updates expected in March. The preliminary figures are subject to change pending final financial reviews, and investors are cautioned not to rely heavily on these early results due to various uncertainties and risks that may affect actual outcomes.
Potential Positives
- Preliminary unaudited net product revenue for XHANCE® was reported at $22.4 million for Q4 2024, aligning with prior guidance.
- Estimation of approximately 20% sequential growth in XHANCE prescriptions from Q3 to Q4 2024 indicates positive commercial execution and market acceptance.
- The company shows commitment to transparency by planning to report full financial results and corporate updates in March 2025.
Potential Negatives
- The preliminary revenue figures are unaudited and subject to significant adjustments, cautioning investors against placing undue reliance on them.
- The company highlights potential risks and uncertainties that could lead to materially different actual results compared to the preliminary results, indicating volatility in performance.
- There is no assurance of continued growth, as physician and patient acceptance of XHANCE and reimbursement issues are cited as potential challenges.
FAQ
What is the preliminary revenue for XHANCE in Q4 2024?
Optinose reported preliminary unaudited net product revenue of $22.4 million for XHANCE in the fourth quarter of 2024.
How much did XHANCE prescriptions grow in Q4 2024?
The estimated sequential growth rate for XHANCE prescriptions from Q3 to Q4 2024 is approximately 20%.
When will Optinose release full financial results?
Optinose expects to report full financial results for the fourth quarter of 2024 in March 2025.
Are the Q4 revenue results audited?
No, the preliminary results have not been audited or reviewed by the Company’s independent registered public accounting firm.
What is the main focus of Optinose?
Optinose is focused on serving the needs of patients treated by ear, nose, and throat (ENT) and allergy specialists.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$OPTN Insider Trading Activity
$OPTN insiders have traded $OPTN stock on the open market 7 times in the past 6 months. Of those trades, 0 have been purchases and 7 have been sales.
Here’s a breakdown of recent trading of $OPTN stock by insiders over the last 6 months:
- MICHAEL F III MARINO (Chief Legal Officer & Corp Sec) has traded it 3 times. They made 0 purchases and 3 sales, selling 55,684 shares.
- RAMY A MAHMOUD (Chief Executive Officer) has traded it 3 times. They made 0 purchases and 3 sales, selling 120,921 shares.
- ANTHONY J KRICK (Chief Accounting Officer) sold 6,845 shares.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$OPTN Hedge Fund Activity
We have seen 23 institutional investors add shares of $OPTN stock to their portfolio, and 41 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BLACKROCK, INC. removed 4,495,734 shares (-85.2%) from their portfolio in Q3 2024
- STONEPINE CAPITAL MANAGEMENT, LLC added 3,338,580 shares (+142.1%) to their portfolio in Q3 2024
- NANTAHALA CAPITAL MANAGEMENT, LLC added 937,963 shares (+7.0%) to their portfolio in Q3 2024
- GREAT POINT PARTNERS LLC removed 865,961 shares (-6.3%) from their portfolio in Q3 2024
- ROSALIND ADVISORS, INC. added 740,355 shares (+9.8%) to their portfolio in Q3 2024
- J. GOLDMAN & CO LP added 675,000 shares (+inf%) to their portfolio in Q3 2024
- FMR LLC added 518,610 shares (+3.2%) to their portfolio in Q3 2024
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
YARDLEY, Pa., Jan. 15, 2025 (GLOBE NEWSWIRE) --
Optinose
(NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced preliminary unaudited XHANCE
®
(fluticasone propionate) net product revenue of $22.4 million for the three months ended December 31, 2024.
“Our preliminary unaudited fourth quarter net product revenue of $22.4 million is in line with our prior guidance and demonstrates a sustained growth in XHANCE prescriptions through the fourth quarter of 2024,” stated CEO Ramy Mahmoud. “For prescriptions, we estimate an approximately 20% sequential growth rate from third quarter to fourth quarter 2024, which is encouraging as we continue to focus on commercial execution and continued growth in the year ahead. We look forward to reporting full financial results for fourth quarter 2024 and corporate updates in March.”
The fourth quarter net product revenue and prescription growth rate included in this press release are preliminary results based on the information available to the Company at this time. Actual results may vary materially from the preliminary results presented in this press release due to the completion of the Company’s financial closing procedures, review adjustments and other developments or information that may arise between now and the time the Company’s financial results for fourth quarter 2024 are finalized. Additionally, the preliminary results have not been audited or reviewed by the Company’s independent registered public accounting firm. Accordingly, you should not place undue reliance on this preliminary data. The Company expects to report full financial results for the fourth quarter of 2024 and corporate updates in March.
About Optinose
Optinose is a specialty pharmaceutical company focused on serving the needs of patients cared for by ear, nose and throat (ENT) and allergy specialists. To learn more, please visit
www.optinose.com
or follow us on
X
and
LinkedIn
.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements that are not historical facts are hereby identified as forward-looking statements for this purpose and include, among others, statements relating to: preliminary unaudited XHANCE net revenue and prescription growth for the three months ended December 31, 2024; sustained growth in XHANCE prescriptions through the fourth quarter of 2024; the Company’s focus on commercial execution and continued growth in 2025; the Company’s expectation to report full financial results for fourth quarter 2024 and corporate updates in March; and other statements regarding the Company's future operations, financial performance, financial position, prospects, objectives, strategies and other future events. Forward-looking statements are based upon management’s current expectations and assumptions and are subject to a number of risks, uncertainties and other factors that could cause actual results and events to differ materially and adversely from those indicated by such forward-looking statements including, among others: the potential for the preliminary unaudited XHANCE net product revenue for the three months ended December 31, 2024 to change in connection with the finalization of the Company’s financial results for such period and review/audit by the Company’s independent registered public accounting firm, and the potential for preliminary estimated XHANCE prescription growth for the three months ended December 31, 2024 to change in connection with finalization of third-party inventory and prescription data as well as data from the Company’s hub and PPN partners, as well as, in each case, other developments or information that may arise between now and the time the Company’s financial results for fourth quarter 2024 are finalized; physician and patient acceptance of XHANCE for its new indication; the Company’s ability to maintain adequate third-party reimbursement for XHANCE (including its new indication); the prevalence of chronic sinusitis and market opportunities for XHANCE may be smaller than expected; the Company’s ability to efficiently generate XHANCE prescriptions and net revenues; and the risks, uncertainties and other factors discussed under the caption "Item 1A. Risk Factors" and elsewhere in the Company’s most recent Form 10-K and Form 10-Q filings with the Securities and Exchange Commission - which are available at www.sec.gov. As a result, you are cautioned not to place undue reliance on any forward-looking statements. Any forward-looking statements made in this press release speak only as of the date of this press release (January 15, 2025), and the Company undertakes no obligation to update such forward-looking statements, whether as a result of new information, future developments or otherwise.
Optinose Investor Contact
Jonathan Neely
jonathan.neely@optinose.com
267.521.0531
This article was originally published on Quiver News, read the full story.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
